Mitchell Imogen, Finfer Simon, Bellomo Rinaldo, Higlett Tracey
The Canberra Hospital, Intensive Care Unit, Garran, 2605, ACT, Australia.
Intensive Care Med. 2006 Jun;32(6):867-74. doi: 10.1007/s00134-006-0135-4. Epub 2006 Apr 19.
To document current management of blood glucose in Australian and New Zealand intensive care units (ICUs) and to investigate the association between insulin administration, blood glucose concentration and hospital outcome.
Practice survey and inception cohort study in closed multi-disciplinary ICUs in Australia and New Zealand.
Twenty-nine ICU directors and 939 consecutive admissions to 29 ICUs during a 2-week period.
Data collected included unit approaches to blood glucose management, patient characteristics, blood glucose concentrations, insulin administration and patient outcomes. Ten percent of the ICU directors reported using an intensive insulin regimen in all their patients. In 861 patients (91.7%) blood glucose concentration was greater than 6.1[Symbol: see text]mmol/l, 287 (31.1%) received insulin, and the median blood glucose concentration triggering insulin administration was 11.5 (IQR 9.4-14) mmol/l. Univariate analysis demonstrated that non-survivors had a higher maximum daily blood glucose concentration (12 mmol/l, 9.4-14.8, vs. 9.5, 7.6-12.2) and were more likely to receive insulin (47% vs. 28%). Multiple logistic regression analysis showed age (OR per 5-year decrease 0.93, 95% CI 0.87-1.00) and APACHE II (OR per point decrease 0.87, 95% CI 0.84-0.90) to be independently associated with hospital mortality. After controlling for age and APACHE II both daily highest blood glucose (OR 0.95, 95% CI 0.90-1.00) and administration of insulin (OR 0.62, 95% CI 0.39-1.00) were independently associated when added to the model alone; neither was independently associated when they were simultaneously included in the model.
Few Australian and New Zealand ICUs have adopted intensive insulin therapy. In this study, insulin administration and highest daily blood glucose concentration could not be separated in their association with hospital mortality.
记录澳大利亚和新西兰重症监护病房(ICU)当前的血糖管理情况,并调查胰岛素使用、血糖浓度与医院结局之间的关联。
在澳大利亚和新西兰封闭的多学科ICU中进行实践调查和初始队列研究。
29位ICU主任以及在两周内29个ICU连续收治的939例患者。
收集的数据包括各科室血糖管理方法、患者特征、血糖浓度、胰岛素使用情况及患者结局。10%的ICU主任报告称在其所有患者中均采用强化胰岛素治疗方案。在861例患者(91.7%)中,血糖浓度高于6.1[符号:见正文]mmol/L,287例(31.1%)接受了胰岛素治疗,触发胰岛素治疗的血糖浓度中位数为11.5(四分位间距9.4 - 14)mmol/L。单因素分析表明,未存活者的每日最高血糖浓度更高(12 mmol/L,9.4 - 14.8,对比9.5,7.6 - 12.2),且更有可能接受胰岛素治疗(47%对比28%)。多因素逻辑回归分析显示,年龄(每降低5岁的比值比为0.93,95%置信区间0.87 - 1.00)和急性生理与慢性健康状况评分系统II(APACHE II,每降低1分的比值比为0.87,95%置信区间0.84 - 0.90)与医院死亡率独立相关。在控制年龄和APACHE II后,每日最高血糖(比值比0.95,95%置信区间0.90 - 1.00)和胰岛素使用(比值比0.62,95%置信区间0.39 - 1.00)单独加入模型时均与死亡率独立相关;当它们同时纳入模型时,两者均与死亡率无独立相关性。
澳大利亚和新西兰很少有ICU采用强化胰岛素治疗。在本研究中,胰岛素使用和每日最高血糖浓度与医院死亡率之间的关联无法区分开来。